Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Nursing | Pharmacy | Urology | Journal

Back to Journal Articles

Tadalafil Effective, Safe in Complete Erectile Dysfunction

Last Updated: October 12, 2012.

 

Intercourse success rates of 32 to 46 percent achieved with tadalafil, with good tolerability

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In men with complete erectile dysfunction, tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.

FRIDAY, Oct. 12 (HealthDay News) -- In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.

Ridwan Shabsigh, M.D., of the Maimonides Medical Center in New York City, and colleagues conducted a post-hoc, pooled analysis of results from four randomized, double-blind trials evaluating the effects of tadalafil 2.5 or 5 mg compared with placebo in men with complete ED (no successful intercourse attempts at baseline).

After 12 weeks of once-daily treatment with tadalafil, the researchers found that the mean per-patient Sexual Encounter Profile question 3 (SEP3) increased from 0 percent to 32.4 and 46.4 percent with 2.5 and 5 mg tadalafil, respectively. The SEP2 (successful penetration) increased from 21.1 to 48.2 percent and 24.4 to 66.2 percent with 2.5 and 5 mg tadalafil, respectively. The mean International Index of Erectile Function increased significantly with 2.5 and 5 mg tadalafil versus placebo. Compared with placebo, improvements were also noted in intercourse-satisfaction and overall-satisfaction domains. Tadalafil was well tolerated with no increase in adverse events versus placebo.

"Once-daily tadalafil 2.5 or 5 mg significantly enhanced erectile function (versus placebo) across all coprimary and secondary efficacy end points in this analysis, and was generally well tolerated," the authors write.

The four base studies and the reported analysis were sponsored by Eli Lilly; several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures tadalafil.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Methotrexate Use Linked to Reduced Mortality in RA Next: Filaggrin Mutations Up Risk of Irritant Contact Dermatitis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.